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Mycobacterium tuberculosis (M. tuberculosis) is considered innately resistant to β-lactam antibiotics. However,
there is evidence that susceptibility to β-lactam antibiotics in combination with β–lactamase inhibitors is vari-
able among clinical isolates, and these may present therapeutic options for drug-resistant cases. Here we report
our investigation of susceptibility to β-lactam/β–lactamase inhibitor combinations among clinical isolates ofM.
tuberculosis, and the use of comparative genomics to understand the observed heterogeneity in susceptibility.
Eighty-nine South African clinical isolates of varying ﬁrst and second-line drug susceptibility patterns and two
reference strains ofM. tuberculosis underwent minimum inhibitory concentration (MIC) determination to two
β-lactams: amoxicillin and meropenem, both alone and in combination with clavulanate, a β–lactamase inhibi-
tor. 41/91 (45%) of tested isolates were found to be hypersusceptible to amoxicillin/clavulanate relative to refer-
ence strains, including 14/24 (58%) of multiple drug-resistant (MDR) and 22/38 (58%) of extensively drug-
resistant (XDR) isolates. Genome-wide polymorphisms identiﬁed using whole-genome sequencing were used
in a phylogenetically-aware linear mixed model to identify polymorphisms associated with amoxicillin/
clavulanate susceptibility. Susceptibility to amoxicillin/clavulanate was over-represented among isolates within
a speciﬁc clade (LAM4), in particular among XDR strains. Twelve sets of polymorphisms were identiﬁed as puta-
tive markers of amoxicillin/clavulanate susceptibility, ﬁve of which were conﬁned solely to LAM4. Within the
LAM4 clade, ‘paradoxical hypersusceptibility’ to amoxicillin/clavulanate has evolved in parallel to ﬁrst and sec-
ond-line drug resistance. Given the high prevalence of LAM4 among XDR TB in South Africa, our data support
an expanded role for β-lactam/β-lactamase inhibitor combinations for treatment of drug-resistant M.
tuberculosis.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Approximately one third of the global population is infected with
Mycobacterium tuberculosis (M. tuberculosis), the etiologic agent respon-
sible for tuberculosis (TB). While many individuals who harbourM. tu-
berculosis never develop active disease, TB is often lethal and is
estimated to have been responsible for 1.5 million deaths in the year
2013 (WHO, 2014). Multidrug-resistant (MDR) TB, which is deﬁned as
in vitro resistance to both rifampin and isoniazid, is a public health prob-
lem of increasing importance, with an estimated 480,000 incident cases
in 2013 (WHO, 2014). Treatment of drug-resistant TB is more complex,
lengthy, costly, toxic, and ultimately less successful at eradicating M.
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tuberculosis infection. With few novel antitubercular antibiotics in
development, the emergence of extensively drug-resistant (XDR)
M. tuberculosis strains (deﬁned as MDR with additional resistance
to both quinolones and second-line injectable agents) and the lack
of effective treatment regimens have highlighted the potential to
repurpose existing antibiotics in innovative ways (Wong et al.,
2013).
M. tuberculosis has been considered innately resistant to β-lactam
antibiotics, due to β–lactamase activity and the presence of non-classi-
cal transpeptidases in their cell wall (Hugonnet et al., 2009; Gupta et
al., 2010). M. tuberculosis possesses a highly active β-lactamase, BlaC,
that rapidly hydrolyzes many β-lactam drugs, rendering them ineffec-
tive (Hugonnet et al., 2009). Additionally, the existence of non-classical
transpeptidases that crosslink the peptidoglycan cell wall ofM. tubercu-
losis are thought to contribute to innate resistance to β-lactams (Gupta
et al., 2010; Dubée et al., 2012).
Despite these barriers, there may be opportunities for clinical treat-
ment of drug-resistantM. tuberculosiswith β-lactam antibiotics (Payen
et al., 2012; Keener, 2014). The addition of clavulanate, an oral β-
lactamase inhibitor, irreversibly inhibits BlaC, and can enhance β-lac-
tam activity against M. tuberculosis in vitro (Wang et al., 2006;
Hugonnet and Blanchard, 2007). Furthermore, the carbapenem class
of β-lactams is relatively resistant to hydrolysis by β-lactamases, and
addition of clavulanate has been shown to further decrease the mini-
mum inhibitory concentration (MIC) (Hugonnet et al., 2009).
Meropenem/clavulanate has been shown to have high in vitro activity
against XDR strains, but its high cost and intravenous dosing present
challenges to its widespread use (Hugonnet et al., 2009; Gonzalo and
Drobniewski, 2013). The laboratory strain of M. tuberculosis, H37Rv,
and multiple drug-susceptible clinical isolates have been shown to be
resistant to β-lactams as well as β-lactams plus β-lactamase inhibitors
in vitro, but it is not yet clear to what extent the wider M. tuberculosis
population may be susceptible to these antibiotics. If drug-resistant
strains are generally more susceptible to this antibiotic class, then one
might envision an expanded role for β-lactams in the treatment of
drug-resistant TB, for which currently there are limited treatment
options.
Here we describe an investigation of 89 South African clinical iso-
lates and two reference strains ofM. tuberculosis of varying drug sus-
ceptibility patterns. We determined the range of MICs to clinically
available β-lactam antibiotics and used whole-genome sequencing
(WGS) to understand the genetic basis of variability with respect
to amoxicillin/clavulanate susceptibility. Our results provide insight
into the clinical role of β-lactams in the treatment of drug-resistant
TB and potential molecular markers of amoxicillin/clavulanate
susceptibility.
2. Methods
2.1. Clinical Isolates of M. tuberculosis
We selected a subset of 86 clinical isolates ofM. tuberculosis fromour
larger sequenced strain set (Cohen et al., 2015) for inclusion in this
study. Brieﬂy, sputum specimens were collected in KwaZulu-Natal,
South Africa from 2008 to 2012 as part of a provincial drug-resistance
surveillance study (Bantubani et al., 2014) and a prospective collection
effort of patients newly initiating XDR regimens (OʼDonnell et al.,
2014). Biomedical Research Ethics Council (BREC) approval from
the University of KwaZulu-Natal was granted for whole genome se-
quencing of clinical strains. On all study isolates, drug susceptibility
testing by critical concentration was performed prospectively for
ﬁrst and second-line TB drugs. The clinical isolate set represented
diverse ﬁrst and second-line drug susceptibility patterns, with 18
susceptible, three mono-drug resistant, ﬁve poly-drug resistant,
23 MDR and 37 XDR isolates.
2.2. Additional M. tuberculosis Strain
In addition to 86 clinical isolates recently isolated in South Africa, we
also selected ﬁve additional strains for inclusion in this study, for a total
of 91 unique isolates. These included reference strains H37Rv and
CDC1551, which are both known to be fully susceptible to ﬁrst and sec-
ond-line TBdrugs. Additionally, three clinical isolates that had previous-
ly been collected in KwaZulu-Natal (Koenig, 2007; Ioerger et al., 2009)
were resequenced and included in this study. These were KZN4207,
KZN1435 and KZN605, which have ﬁrst/second-line drug susceptibility
patterns of: susceptible, MDR and XDR, respectively.
2.3. β-lactam MIC Determination
TheWorldHealth Organization (WHO) does not recommend a stan-
dard methodology for β-lactam susceptibility or resistance testing inM.
tuberculosis, thus we utilized theMicroplate Alamar Blue Assay (MABA)
(Collins and Franzblau, 1997) to determine the MIC of each strain to β-
lactams alone, or β-lactams in combination with clavulanate, a β-
lactamase inhibitor, as previously described (Lun et al., 2013). The β-
lactams and concentrations utilized were amoxicillin (0.5 μg/mL to
32 μg/mL) and meropenem (0.25 μg/mL to 16 μg/mL). Brieﬂy, 104 colo-
ny forming units (CFU) of a mid to late-log culture of each strain was
plated onto a 96-wellmicroplate in the presence of serial drug-dilutions
with or without 2.5 μg/mL of clavulanate. Following seven days in cul-
ture, the lowest concentration of drug leading to at least a 90% reduction
of bacterial growth signal byMABAwas recorded as theMIC. Each assay
was performed between one to 6 times on each isolate.
2.4. β-lactam Susceptibility Deﬁnitions
Based on favourable pharmacokinetics that would be necessary for
clinical treatment (White et al., 2004), susceptibility to amoxicillin
was deﬁned as an MIC ≤4.0 μg/mL, and resistance as an MIC N4.0 μg/
mL; susceptibility to amoxicillin/clavulanate was deﬁned as an MIC
≤4.0 μg/mL/2.5 μg/mL, and resistance as an MIC N4.0 μg/mL/2.5 μg/mL.
Susceptibility to meropenem was deﬁned as an MIC ≤12.0 μg/mL, and
resistance as an MIC N12.0 μg/mL; susceptibility to meropenem/
clavulanate was deﬁned as an MIC ≤12.0 μg/mL/2.5 μg/mL, and resis-
tance as an MIC N12.0 μg/mL. We note that our association analysis
used the amoxicillin/clavulanate MIC values directly, without dichoto-
mization of resistant vs. susceptible.
2.5. β-lactamase Activity Testing
A subset of 10M. tuberculosis isolates with varying average MICs to
amoxicillin/clavulanate (range 0.5 μg/mL to N32 μg/mL of amoxicillin
in combinationwith 2.5 μg/mL clavulanate) underwent qualitative test-
ing of their β-lactamase activity by nitroceﬁn hydrolysis. Nitroceﬁn
(Calbiochem), a chromogenic β-lactamase substrate, was reconstituted
in dimethyl sulfoxide (DMSO) to achieve 1 mg/mL. 60 μL of nitroceﬁn
was diluted into 3 mL of phosphate buffered saline (PBS) nitroceﬁn to
create a working solution. Mid to late log cultures of M. tuberculosis
were diluted in PBS, and 105 colony forming units of each strain were
plated into a 96-well plate. 100 μL of the nitroceﬁn working solution
was added. Cultures were monitored for a color change from yellow
to red that occurs with nitroceﬁn hydrolysis.
2.6. Whole-genome Sequencing
Whole-genome sequencing had been performed on all included
strains as previously described and published in Cohen et al. (Cohen et
al., 2015). Brieﬂy, mycobacterial strains were single colony selected,
and genomic DNA was extracted using published methods (Larsen et
al., 2007). Library preparation andwhole-genome sequencingwere per-
formed on the IlluminaHiSeq 2000 at the Broad Institute in Boston,MA,
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as previously described (Walker et al., 2014). Both short (180 bp) and
large (3–5Kbp) insert paired-end librarieswere created fromeach sam-
ple and sequenced using a read length of 101 bp. All sequencing data
were retrieved from the Sequence Read Archive NCBI umbrella
BioProject identiﬁer PRJNA183624.
2.7. In silico Spoligotyping
In vitro spoligotypes are derived by a hybridization assay which de-
termines whether or not each of 43 probe sequences (each 25 bp in
length) hybridizes against a sample of DNA (Kamerbeek et al., 1997).
Here spoligotypes were determined in silico from Illumina sequence
reads by extraction of 25 bp sequences and their reverse complements
from all possible positions, and subsequent search across this set for a
match for each probe sequence. In the in vitro assay, probesmay hybrid-
ize even if the sequences do not match exactly, and thus we allowed up
to two nucleotide mismatches per probe. Hybridization patterns were
assigned to known M. tuberculosis clades/lineages by comparison of
exact pattern matches in the international SITVIT database (Demay et
al., 2012) and interrogation of the TB Insight: TB-Lineage database
(Shabbeer et al., 2012). Lineage designations were converted to the
standardised nomenclature as presented in Gagneux et al. (Gagneux
and Small, 2007).
2.8. Single nucleotide variant calling
Illumina reads for each of 91 strains were trimmed using seqtk
(https://github.com/lh3/seqtk version 1.0-r31) with a Phred quality
threshold of 0.01. Trimmed reads were mapped to the H37Rv reference
genome (accession NC_000962.3) using BWA (Li and Durbin, 2009).
Subsequent processing by SAMTools (Li et al., 2009) removed duplica-
tions, merged reads from different sequencing runs of the same isolate
and removed unpaired reads. SNPs and small indels (SNVs) were called
using SNVer (Wei et al., 2011) in a monoploid mode with default pa-
rameters, with the exception that the minimum base quality threshold
was increased to q20. We also enforced a minimum frequency of ﬁve
reads, in each of the forward and reverse orientations, supporting
each SNV call. Variants for which the maximum a-posteriori genotype
estimation as computed by SNVer did not support any allele, for
which depth was less than 10, strand bias was smaller than 0.05, or
p N 10−10 were excluded from subsequent analyses.
2.9. Phylogenetic Reconstruction
Bayesian inference of phylogeny as implemented in MrBayes
(Ronquist et al., 2012) was performed based on substitution patterns
of single nucleotides at conserved genomic sites (i.e. forwhich high con-
ﬁdence SNP calls were obtained across all isolates). Genomic regions
that are known to be prone to erroneous mapping of reads, namely re-
peat regions, mobile elements, phage proteins, PE and PPE proteins,
were excluded (Casali et al., 2012). Mycobacterium canettii CIPT
140010059 (accession: NC_015848)was used as an outgroup for phylo-
genetic reconstruction. A generalized time-reversible (GTR) evolu-
tionary model with gamma distributed rate variation across sites
was applied (1,000,000 Markov chain Monte Carlo runs sampled
every 1000 generations after a relative burn-in of 0.25, yielding a
total of 750 replicates). As association tests require a phylogeny
that estimates relatedness among isolates in terms of evolutionary
time (Kang et al., 2008), a molecular clock constraint was imposed
on branch lengths, enforcing all the leaves to be equidistant from
the root. For visualization purposes, a tree with branch lengths
that reﬂected the number of substitutions was also inferred (Figs.
2 and 3).
2.10. Gene-content Analysis
De novo sequence assemblies were annotated by Prokka (Seemann,
2014). Nucleotide sequences for all annotated coding sequence (CDS)
regions were added to those annotated within 18M. tuberculosis refer-
ence genomes retrieved from Genbank (accessions; NC_000962.3, NC_
002755.2, NC_009565.1, NC_012943.1, NC_016768.1, NC_016934.1,
NC_017522.1, NC_017523.1, NC_017524.1, NC_018078.1, NC_020089.
1, NC_020559.1, NC_021054.1, NC_021192.1, NC_021193.1, NC_
021194.1, NC_021740.1, NC_022350.1). A BLASTn all-against-all analy-
sis was used to cluster CDS (percentage identity ≥90% and coverage
≥85%). Single representatives of each cluster were collated to form a
non-redundant CDS list (preferentially selecting H37Rv reference CDS
when present within a cluster). Non-H37Rv cluster representatives
were screened against the H37Rv reference genome and removed if
there was a BLASTn match with ≥90% identity and ≥85% coverage.
(The H37Rv genome annotation has been well curated and thus we as-
sume any sequence showing homology to regions of this genome, but
whichhas not been annotated as a CDS in this genome, represents an er-
roneous annotation.) The presence of sequence regions representing
each of the ﬁltered, non-redundant CDS clusters (n = 3957) was esti-
mated by BLASTn search against the de novo genome assemblies (per-
centage identity ≥90%, coverage ≥85%). Genes were considered
putatively absent in cases where there was no BLAST match above the
identity and coverage thresholds.
2.11. Association Tests
Genomic variants were tested for association with log MIC to amox-
icillin/clavulanate. The association analysis used the amoxicillin/
clavulanateMIC values directly rather than the dichotomous phenotype
of resistant vs. susceptible. All SNVs for which base calls were available
in all isolateswere included in the analysis (including those in repeat re-
gions,mobile elements, phage and PE/PPE genes). All genes represented
by CDS in the ﬁltered non-redundant list (see above)were also included
in the analysis.
The initial sample consisted of 8580 SNVs and 8936 gene-content
patterns. After excluding low frequency variants in which less than
three isolates varied from all other isolates, 2555 SNVs and 228 gene-
content patterns remained in the analysis. The close relatedness be-
tween many of the isolates in our sample leads to strong statistical de-
pendencies between many pairs of variants, whose alleles have the
same patterns across the sample. Such variants by deﬁnition comprise
the same statistical hypothesis and result in the same p-value. We
thus performed analysis of unique variant patterns, rather than of in-
dividual variants, and attached the p-value of each unique pattern to
all SNVs having this pattern. Overall, 239 SNV patterns and 122 gene-
content patterns (with an overlap of four patterns) were tested for
association with drug resistance. FDR analysis was performed by
considering the total number of tested hypotheses under both
analyses.
A major challenge of genome-wide association testing is the
presence of a population structure (Chen and Shapiro, 2015) in
which sampled isolates are not identically and independently dis-
tributed. This can lead to spurious results due to confounding, e.g.
in this case alleles that are common to a group of closely related sus-
ceptible isolates may falsely appear to be associated with ß-lactam
susceptibility. To account for population structure in the setting of
a quantitative phenotype (e.g. log-MIC), we applied a phylogeneti-
cally aware LMM (Kang et al., 2008). Given that M. tuberculosis is
known to have a low rate of horizontal gene transfer (Liu et al.,
2006), the effect of the population structure is assumed to be well-
approximated by phylogeny. p-values were computed via simula-
tion testing with one million simulations. See Supplemental
Methods for more details.
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3. Results
3.1. Clinical Isolates of M. tuberculosis Exhibit a Broad Range of MICs to β-
lactams
We screened a set of 91M. tuberculosis strains of varying drug sus-
ceptibility patterns by determining theMIC toβ-lactam/β-lactamase in-
hibitor combinations (Table S1). Included clinical isolates of M.
tuberculosis had been collected from 2008 to 2012 in KwaZulu-Natal,
South Africa (Cohen et al., 2015). Phenotypic assessment of a strain's
susceptibility to amoxicillin, amoxicillin/clavulanate, meropenem and
meropenem/clavulanatewas performed by the drugMicroplate Alamar
Blue Assay (MABA), as previously described (Collins and Franzblau,
1997; Lun et al., 2014).
Phenotypic testing of strains revealed universally high MICs to
amoxicillin by itself (Fig. 1A), which conﬁrms innate mycobacterial re-
sistance to this antibiotic alone among these strains. However, with
the addition of clavulanate the mean MIC to amoxicillin lowered from
55.4 to 15.2 (Table S2), as numerous isolates were observed to have
very lowMICs to amoxicillin/clavulanate (Fig. 1B). With drug combina-
tion amoxicillin/clavulanate, 41/91 (45%) isolates had anMIC ≤4 μg/mL/
2.5 μg/mL and as such were classiﬁed as susceptible to this regimen
(Table 1; Table S1). Given thewide range ofMICs observed for amoxicil-
lin/clavulanate, a signiﬁcant number ofM. tuberculosis isolates may be
amenable to treatment with this orally active β-lactam/β-lactamase in-
hibitor combination.
MIC determination was also performed for meropenem and
meropenem/clavulanate. With meropenem alone, there was also a
range of MICs observed among the tested isolates (Fig. 1C). With addi-
tion of clavulanate to meropenem (Fig. 1D), the mean observed MIC
was lowered from 22.0 μg/mL for meropenem alone to 5.4 μg/mL/
2.5 μg/mL for meropenem/clavulanate (Table S2). The resulting MIC's
to meropenem and meropenem/clavulanate were consistent with
those derived in a previous study (Hugonnet and Blanchard, 2007).
3.2. Paradoxical Hypersusceptibility to β-lactams among MDR and XDR
Isolates
Interestingly, strains that had previously been classiﬁed as MDR or
XDR on ﬁrst and second-line TB drug susceptibility testing were more
frequently associated with amoxicillin/clavulanate susceptibility than
isolates that were fully susceptible to ﬁrst and second-line drugs
(Table 1). 14/24 (58%) MDR and 22/38 (58%) XDR isolates were classi-
ﬁed as susceptible to amoxicillin/clavulanate, whereas only 3/21 (14%)
ﬁrst-line drug susceptible isolates were classiﬁed as susceptible to the
same drug combination. Given that the overwhelming majority (18/
21, 86%) of ﬁrst-line susceptible strains including the reference labora-
tory strains H37Rv and CDC1551 were resistant to amoxicillin/
clavulanate, it appeared paradoxical that MDR and XDR isolates would
be susceptible to this drug combination. This was therefore termed “hy-
persusceptibility,” to indicate gain of susceptibility.
3.3. In vitro Assessment of β-lactamase Activity
To determine whether observed differences in the MIC to amoxicil-
lin/clavulanate were due to differential β-lactamase activity, a pheno-
typic assessment was performed by the nitroceﬁn hydrolysis assay
(see Section 2). A subset of 10 isolates with varying drug susceptibility
patterns and a range of MICs to amoxicillin/clavulanate were selected
for assessment (Table S3). All assayed strains, irrespective of drug
Fig. 1A–1D. Clinical isolates of M. tuberculosis exhibit a range of susceptibility to β-lactam/β-lactamase inhibitors. 91 isolates of M. tuberculosis underwent MIC determination to A)
amoxicillin, B) amoxicillin/clavulanate, C) meropenem, and D) meropenem/clavulanate. MICs are reported by β-lactam concentration, and clavulanate concentration was held constant
at 2.5 μg/mL.
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susceptibility pattern orMIC to amoxicillin/clavulanatewere able to hy-
drolyze nitroceﬁn, indicative of positive β-lactamase activity. This sug-
gested that lack of β-lactamase activity did not account for low MICs
to amoxicillin/clavulanate. These results are consistent with our obser-
vation that clavulanate addition is necessary to achieve a low MIC to
amoxicillin.
3.4. Population Structure Reveals a Monophyletic Clade of LAM4 MDR and
XDR Strains
We conducted a comparative genomic analysis to understand the
evolution of hypersusceptibility to amoxicillin/clavulanate in our
panel of clinical isolates. All 91 β-lactam phenotyped strains had
Table 1
Adisproportionate number ofMDR andXDR strainswere susceptible to amoxicillin/clavulanate. Susceptibility to amoxicillin or amoxicillin/clavulanatewasdeﬁned asMIC ≤4 μg/mL of the
amoxicillin component. Susceptibility to meropenem or meropenem/clavulanate was deﬁned as MIC ≤12 μg/mL of the meropenem component. Clavulanate was 2.5 μg/mL.
First and second-line DST category Amoxicillin susceptibility Amoxicillin/Clavulanate susceptibility Meropenem susceptibility Meropenem/Clavulanate susceptibility
Susceptible 0/21 (0%) 3/21 (14%) 3/16 (19%) 14/16 (87.5%)
Mono-drug resistant 0/3 (0%) 0/3 (0%) 0/3 (0%) 3/3 (100%)
Poly-drug resistant 0/5 (0%) 2/5 (40%) 1/5 (20%) 5/5 (100%)
MDR 0/24 (0%) 14/24 (58%) 5/18 (28%) 19/21 (90%)
XDR 1/38 (3%) 22/38 (58%) 11/36 (31%) 36/37 (97%)
Total 1/91 (1%) 41/91 (45%) 20/78 (26%) 77/82 (94%)
Fig. 2. Amoxicillin/clavulanate hypersusceptible isolates were largely clustered within a monophyletic XDR group within the LAM4 clade. A Bayesian phylogeny of 91M. tuberculosis
isolates, rooted with the M. canettii outgroup, is shown. Bootstrap support values N80% are marked by an asterisk. Globally recognised M. tuberculosis lineages are indicated.
Amoxicillin/clavulanate MICs are represented in a horizontal bar graph to the right of the tree. MICs are reported by amoxicillin concentration, and clavulanate concentration was held
constant at 2.5 μg/mL. As indicated in the ﬁgure key, the MIC bar graph is color-coded according to the ﬁrst and second-line drug susceptibility patterns of the corresponding strain.
The shaded box indicates LAM4 strains; a monophyletic cluster of spoligotype LAM4 strains with MDR and XDR level resistance is observed within lineage 4. While a signiﬁcant
number of isolates with hypersusceptibility to amoxicillin/clavulanate were concentrated within the LAM4 XDR clade, there are other notable examples of hypersusceptible strains
that pertain to other global lineages and spoligotypes.
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whole-genome sequences available for analysis (Cohen et al., 2015). A
Bayesian phylogeny (Fig. 2) was inferred from 7005 polymorphic sites
identiﬁed through read-mapping and variant calling (Methods).
In parallel, we performed an in silico spoligotype prediction
(Methods) to contextualize the resulting population structure
with respect to previously deﬁned global M. tuberculosis lineages
(Gagneux and Small, 2007; Hershberg et al., 2008) and SITVIT
clades (Demay et al., 2012; Shabbeer et al., 2012). Strains represent-
ed 15 distinct shared types distributed across 11 SITVIT clades, each
nesting within one of four global M. tuberculosis lineages (Table 2;
Table S1).
There was an asymmetric distribution of MDR and XDR observed
across the phylogeny (Fig. 2), as a disproportionate number of MDR
and XDR isolates pertained to Lineage 4. More speciﬁcally, in silico
spoligotyping revealed that these strains pertained to the LAM4
SITVIT clade and accounted for a great majority of MDR and XDR
among the study isolates, with 68% and 85%, respectively. Of note,
the LAM4 XDR strains clustered phylogenetically with reference
strain KZN605 (Koenig, 2007; Ioerger et al., 2009), which was isolat-
ed in Tugela Ferry, KZN, South Africa in 2005 during the famed nos-
ocomial XDR outbreak (Gandhi et al., 2006). A prior sequencing
study by Cohen et al. (2015) has demonstrated that these same iso-
lates are members of the clonal Tugela Ferry XDR epidemic in the
region.
3.5. β-lactamHypersusceptibility is ConcentratedWithin the Monophyletic
Cluster of LAM4
While at least one strain susceptible to amoxicillin/clavulanate was
observed in each of Lineages 1, 2 and 4, the vast majority (37/41
[90.2%]) of susceptible strains fell within Lineage 4 (Fig. 2 and Table
2). In fact, 32/41 (78%) of amoxicillin/clavulanate susceptible isolates
pertained to the LAM4 clade, suggesting a monophyletic origin of
hypersusceptibility.
In general, it can be difﬁcult to disambiguate which genetic variants
are responsible for a speciﬁc trait within a monophyletic clade as all ge-
netic elements shared among the cladememberswill appear to be asso-
ciated with that trait. However, the substantial phenotypic variability
with respect to amoxicillin/clavulanate MIC despite limited genotypic
variability in the LAM4 clade was suggestive that it may still be possible
to identify key genomic variants responsible for or markers of the
phenotype.
3.6. Comparative Genomic Analysis: Application of a Phylogenetically-
aware Linear Mixed Model to Identify Candidate Variants
We next sought to test genomic markers of amoxicillin/clavulanate
susceptibility using a phylogenetically-aware linear mixed model
(LMM) (Kang et al., 2008) to identify candidate genomic variants. As
our sample was dominated by a monophyletic phenotype of hypersus-
ceptibility (Fig. 2), a phylogenetically-aware LMM was selected as this
approach takes the phylogenetic structure into account and allows
ranking of genomic phenotype-differentiating variants while remaining
resilient to spurious variants (Chen and Shapiro, 2015). Single nucleo-
tide polymorphisms (SNPs) and single nucleotide indels were consid-
ered together as single nucleotide variants (SNVs), and the goal of the
analysis was focused on identifying genetic elements that differentiate
closely related isolates that exhibit large phenotypic differences.
Rather than testing each independent SNV, variants were tested in
groups deﬁned by their pattern of representation across the set of ge-
nomes (i.e. variants shared by the same subset of genomes were
grouped together). After excluding variants present in two or fewer ge-
nomes, we identiﬁed 239 distinct SNV groups. Due to the large number
of tested hypotheses relative to the sample size, we controlled for the
false discovery rate (FDR) rather than the family-wise error rate, using
the Benjamini–Hochberg procedure (Benjamini and Hochberg, 1995).
All p-values smaller than 1.68 × 10−3 were determined to be signiﬁcant
at a 5% FDR, yielding 12 signiﬁcant SNV groups. Of note, separately from
the association analysis of SNVs, the LMM was also applied to a gene-
content analysis (See Supplemental Results).
3.7. Identiﬁcation of Twelve Signiﬁcant Groups of Variants by LMMAnalysis
The LMM analysis identiﬁed 12 signiﬁcant groups of variants as
highly associated with amoxicillin/clavulanate susceptibility, one of
which included only a single synonymous variant (Table 3, Tables S4
and S5). These twelve groups with signiﬁcant p-values comprised a
total of 38 individual SNVs which included: 17 non-synonymous muta-
tions within predicted coding sequences, 16 synonymous mutations
(Table S5); four intergenic polymorphisms, and a single nucleotide de-
letion within a predicted pseudogene (PE_PGRS36). Coding sequences
included those associated with the following functions as deﬁned in
the TubercuList database (Lew et al., 2011) or as otherwise cited: ﬁrst
and second-line drug resistance (rpoB, gyrA, ubiA (Saﬁ et al., 2013)), vir-
ulence, transmembrane proteins (ctpB, drrA, Rv3921c) and cell wall
Table 2
Frequency and distribution of DST patterns and amoxicillin/clavulanate susceptibility determination acrossM. tuberculosis global lineages and SITVIT clades.
M. tuberculosis lineage Spoligotype designation Total number of strains per spoligotype
First/second-line DST patterns
Amoxicillin/clavulanate
susceptibilities
Susceptible Mono/Poly MDR XDR Susceptible Resistant
1 EAI1-SOM 2 – 1 (50%) 1 (50%) – 2 (100%) –
2 Beijing 20 6 (30%) 5 (25%) 5 (25%) 4 (20%) 2 (10%) 18 (90%)
3 CAS1-Kili 1 – 1 (100%) – – – 1 (100%)
4 H1 1 1 (100%) – – – 1 (100%) –
H37Rv 2 2 (100%) – – – – 2 (100%)
LAM3 4 3 (75%) – – 1 (25%) – 4 (100%)
LAM4 47 4 (9%) 1 (2%) 13 (28%) 29 (62%) 32 (68%) 15 (32%)
S 4 – – 4 (100%) – 1 (25%) 3 (75%)
T1 3 2 (67%) – 1 (33%) – 1 (33%) 2 (67%)
T3 1 – – – 1 (100%) – 1 (100%)
X3 5 2 (40%) – – 3 (60%) 1 (20%) 4 (80%)
UND 1 1 (100%) – – – 1 (100%) –
Total 91 21 (23%) 8 (9%) 24 (26%) 37 (41%) 41 (45%) 50 (55%)
Lineages and SITVIT clades inferred from in silico spoligotype data (see Section 2). UND= undesignated spoligotype. First/second-line drug susceptibility (DST) results are abbreviated as
follows: susceptible, mono or poly-drug resistant (Mono/Poly), multi-drug resistant (MDR) and extensively drug resistant (XDR). For amoxicillin/clavulanate susceptibility, strains were
designated susceptible and resistant based on an MIC ≤4 μg/mL of the amoxicillin component.
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synthesis (aftD, PE-PGRS genes (Brennan and Delogu, 2002) pks12
(Matsunaga and Sugita, 2012) and ubiA). Asmapping and variant calling
within the PE/PPE genes is notoriously difﬁcult due to extent of se-
quence repeats within these genes, our ﬁndings regarding SNVs in
these genes should be considered cautiously. Intergenic SNVs included
one upstream of mmpL13a, a transmembrane transport protein, and
one within two nucleotides of the espA transcriptional start site (Pang
et al., 2013).
3.8. Clustering of Variants Within pks12 Likely Due to Recombination
Interestingly, eight of the identiﬁed variants were located within a
34 bp region of the 5′ pks12, which included two non-synonymous
and six synonymous mutations. pks12 encodes a polyketide synthetase
required for dimycocerosyl phthiocerol production, a major cell wall
lipid that has been implicated in innate resistance to macrolides inM.
avium (Philalay et al., 2004) and described in other M. tuberculosis
drug-resistant strains (Farhat et al., 2013). This pattern of spatially clus-
tered polymorphisms, previously observed in KZN-R506 (Ioerger et al.,
2009), is highly unexpected, as TB has a low mutation rate. The longest
open reading frame inM. tuberculosis, pks12 spans 12,456 nucleotides
and is composed of two near identical sequences (Fig. S1). Eight of the
SNVs were clustered at 5′ Beta-ketoacyl synthase (bks) domain, after
which the surrounding DNA sequence is identical to the corresponding
sequence at the 3′ bks domain. Taken together, these ﬁndings suggest a
recombination event had occurred rather than multiple independent
pointmutations (Feil et al., 2000). pks12 has been identiﬁed by prior as-
sociation studies inM. tuberculosis (Farhat et al., 2013); however, given
the length of the gene, its association with amoxicillin/clavulanate sus-
ceptibility may well be spurious.
3.9. Amoxicillin/Clavulanate Susceptibility Within the LAM4 Phylogeny
In order to track the co-evolution of amoxicillin/clavulanate hyper-
susceptibility and ﬁrst and second-line drug-resistance within LAM4,
we investigated the signiﬁcant SNVs in relationship to the LAM4
phylogeny (Fig. 3). A key observation was that 21/38 (55%) of the vari-
ants identiﬁed in our analyses were grouped into only four aggregates
(indicated as A to D in Fig. 3), and each associated with a distinct divi-
sion in the LAM4 sub-clade (Table 3). Division B coincided with rpoB
L452, which confers rifampicin resistance and emergence of MDR level
drug-resistance. This analysis suggests that within the LAM4 subclade,
MDR level-resistance and amoxicillin/clavulanate susceptibility appear
to have emerged in tandem.
All the SNVs associated with divisions A–D occurred solely within
the LAM4 clade, thus further analysis in other populations will be re-
quired to determine whether these SNVs represent markers of amoxi-
cillin/clavulanate susceptibility among the broader M. tuberculosis
population.
4. Discussion
The global increase in MDR and XDR TB has prompted investigators
to search for alternative treatment options, including repurposing of
existing antibiotic therapies (Wong et al., 2013). WhileM. tuberculosis
has traditionally been considered resistant to the β-lactams, there is
emerging evidence that meropenem/clavulanate can have anti-tuber-
cular activity relevant to the treatment of XDR-TB (Hugonnet et al.,
2009). However, the extent to which meropenem/clavulanate or other
β-lactam/β-lactamase inhibitor combinations are effective against the
widerM. tuberculosis population is unclear.
We performed a phenotypic screen of 91 M. tuberculosis strains
(Cohen et al., 2015) in order to determine the range of susceptibility
to amoxicillin, amoxicillin/clavulanate, meropenem and meropenem/
clavulanate. As expected, nearly all tested strains (94%) were suscepti-
ble to meropenem/clavulanate. Surprisingly, 45% of strains were also
susceptible to amoxicillin/clavulanate, including a large proportion of
MDRandXDR strains (58% each). Asmeropenem/clavulanate is intrave-
nous, costly, and has multiple potential side effects (Linden, 2007), we
chose to focus our investigation and discussion on amoxicillin/
clavulanate, which is an inexpensive, oral, and globally accessible drug
combination with an excellent safety proﬁle (Salvo et al., 2009).
Table 3
Single nucleotide variants (non-synonymous and intergenic) identiﬁed as putative genomic markers of amoxicillin/clavulanate susceptibility.
Genomic loci Rv number Gene name Effect* Amino acid effect # Isolates p-Value LAM4 sub-clade
664929 Rv0571c-Rv0572c – C➜ A Intergenic 28 1.28E−04 D
761161 Rv0667 rpoB cTg➜ cCg L452P 36 2.40E−04 B
1272321 Rv1144-Rv1145 −mmpL13a C➜ A Intergenic 36 2.40E−04 B
2,300,674 Rv2048c pks12 Aac➜ Gac N2105D 36 2.40E−04 B
2300676 Rv2048c pks12 tAc➜ tTc Y2104F 36 2.40E−04 B
3889150 Rv3471c – gaC➜ gaA D64E 36 2.40E−04 B
761110 Rv0667 rpoB gAc➜ gGc D435G 30 2.88E−04 C
763123 Rv0667 rpoB aTc➜ aCc I1106T 30 2.88E−04 C
2246032 Rv2000 – cTg➜ cCg L275P 30 2.88E−04 C
4056430 Rv3616c-Rv3617 espA-ephA T➜ C Intergenic 30 2.88E−04 C
1212626 Rv1087 PE_PGRS21 gAc➜ gCc D356A 36 3.04E−04 –
7570 Rv0006 gyrA gCg➜ gTg A90 V 32 4.96E−04 –
4269271 Rv3806c ubiA gTg➜ gCg V188 A 31 6.08E−04 –
1532777 Rv1361c PPE19 cAg➜ cGg Q286R 45 1.10E−03 –
122107 Rv0103c ctpB Ggt➜ Agt G23S 42 1.17E−03 A
3272997 Rv2936 drrA Agg➜ Ggg R262G 42 1.17E−03 A
283614 Rv0236c aftD Agc➜ Ggc S1080G 8 1.25E−03 –
340372 Rv0280 PPE3 Tcg➜ Ccg S337P 8 1.25E−03 –
2357269 Rv2098c PE_PGRS36 (pseudogene) G➜ Deletion 8 1.25E−03 –
3462135 Rv3093c – tgC➜ tgG C210W 8 1.25E−03 –
3942640 Rv3512 PE_PGRS56 aTt➜ aCt I306T 8 1.25E−03 –
2074509 Rv1829-Rv1830 – C➜ G Intergenic 45 1.40E−03 –
Genomic loci as deﬁned in theH37Rv reference genome. For single nucleotide polymorphisms ‘Effect’ indicates the base differences (base in reference➜ alternative base), polymorphisms
within coding sequence regions are shown as capital letters in the context of the codons to which they belong (other positions shown in lower case). # Isolates indicates the number ofM.
tuberculosis strains that contained the corresponding polymorphism. LAM4 sub-clade indicates the sub-clade forwhich the SNP in question is both unique to and conserved across the sub-
clade. All SNVshaving the same p-value represent the same evolutionary pattern. Of note, our analyses did not identify any associations between amoxicillin/clavulanate susceptibility and
variation in genes previously implicated for this phenotype e.g.mycobacterial L,D-transpeptidases, carboxypeptidases, penicillin-binding proteins and the BlaC beta-lactamase among
others (Dubée et al., 2012; Datta et al., 2006; Kumar et al., 2012; Flores et al., 2005; Bhakta and Basu, 2002; Danilchanka et al., 2008; Dinesh et al., 2013; Fukuda et al., 2013; McDonough
et al., 2005) (Table S6).
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We sought to further investigate the phenomenon of amoxicillin/
clavulanate susceptibility using comparative genomics. A phylogenetic
analysis indicated that a large proportion of MDR and XDR isolates in
our dataset were part of a LAM4 clade, which was responsible for the
famed Tugela Ferry XDR outbreak in KwaZulu-Natal in 2005 (Gandhi
et al., 2006), and still accounts for a considerable burden of XDR
(Chihota et al., 2012; Müller et al., 2013; Gandhi et al., 2014). Addition-
ally, a large proportion of amoxicillin/clavulanate susceptible isolates
were also members of this clade, raising the possibility that this drug
combination may be of beneﬁt for individuals harboring these strains.
The pharmacodynamics of co-amoxiclav in the treatment of M. tu-
berculosis have not be formally studied. However for most bacteria the
time above MIC (T NMIC) is considered the principal determinant of ef-
ﬁcacy (Turnidge, 1998). The slow growth of M. tuberculosismeans an
extended T NMIC is likely to be critical for this organism. Despite this
multiple and high dosing of co-amoxiclav could achieve drug levels ex-
pected to be active againstM. tuberculosis strains with an MIC of ≤4 μg/
mL/2.5 μg/mL amoxicillin/clavulanic acid (Chierakul et al., 2006).
Next we identiﬁed putative genomic markers of amoxicillin/
clavulanate susceptibility through application of a phylogenetically-
aware linearmixedmodel (LMM), which is suitable for samples where-
in there is a large phenotypic variabilitywithin a group of closely related
isolates (Supplementary material). The LMM identiﬁed 12 candidate
variant patterns, comprising 38 unique variants (Table 3, Table S5). It
should be remembered that despite the use of a phylogenetically-
aware LMM, association analyses cannot separate the effects of genomic
variants that show linkage disequilibrium (i.e. those that represent the
same pattern), a factor which must be considered when interpreting
our results. Consequently, we do not infer causality, but rather suggest
that the variants identiﬁed here represent genomic markers of amoxi-
cillin/clavulanate susceptibility, which warrant further investigation.
Although our analyses did identify a number of interesting variants,
we did not identify any associations between amoxicillin/clavulanate
susceptibility and variation in genes previously implicated for this phe-
notype e.g.mycobacterial L,D-transpeptidases, carboxypeptidases, peni-
cillin-binding proteins (Dubée et al., 2012; Datta et al., 2006; Kumar et
Fig. 3.Tracing the emergence of amoxicillin/clavulanate susceptibilitywithin the LAM4 clade. A. Bayesian phylogeny of 91M. tuberculosis isolates as represented in Fig. 2. The LAM4 clade is
marked by the blue box and is magniﬁed in B. Nodes with bootstrap support values N80% are marked by an asterisk. Nodes A-D deﬁne subclade divisions for which the corresponding
pattern of genomic variants listed in Table 3 is conserved among all members of the subclade. Amoxicillin/clavulanate MICs (amoxicillin μg/mL, clavulanate concentration ﬁxed at
2.5 μg/mL) are represented in a horizontal bar graph to the right of the tree. The bar graph is color-coded according to ﬁrst and second-line drug susceptibility patterns as in Fig. 2.
Historic LAM4 strains are identiﬁed by name: KZN605 (XDR), KZN1435 (MDR) and KZN4207 (ﬁrst/second-line drug susceptible).
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al., 2012; Flores et al., 2005; Bhakta and Basu, 2002; Danilchanka et al.,
2008; Dinesh et al., 2013; Fukuda et al., 2013; McDonough et al.,
2005). Furthermore, we found no evidence that altered β-lactamase ge-
netics or activity accounts for observed differences in amoxicillin/
clavulanate susceptibility. All 91 strains had a wild type blaC, the gene
that encodes for the primary β-lactamase ofM. tuberculosis. All strains
in which β-lactamase activity was assessed—including strains with
low MICs to amoxicillin/clavulanate—demonstrated the ability to hy-
drolyze nitroceﬁn, a β-lactam. Despite these ﬁndings, it is still conceiv-
able that differences in BlaC expression may account for the observed
range of β-lactam susceptibility, a hypothesis thatwill need to be tested
in future experiments.
ForM. tuberculosis,ﬁrst and second-line drug susceptibility conforms
to a classicmodel of drug resistance: wild typeM. tuberculosis is suscep-
tible to ﬁrst and second-line antitubercular drugs (e.g. isoniazid, rifam-
pin, oﬂoxacin, kanamycin etc.), and exposure to these same agents
selects for resistant organisms. In contrast, our documentation ofM. tu-
berculosis susceptibility to amoxicillin/clavulanate does not ﬁt this clas-
sical model. Drug susceptible reference strains of M. tuberculosis and
clinical isolates in basal phylogenetic groups (Figs. 2 and 3) had innate
resistance to amoxicillin/clavulanate, yet clinical isolates were observed
to be susceptible, suggesting that they had acquired susceptibility to
these agents. To distinguish this phenomenon from the classic model
of drug resistance, we have named this concept “paradoxical hypersus-
ceptibility,”whichwe deﬁne as phenotypic drug susceptibility observed
in an organism in which its wild type state has innate resistance to that
respective drug.
Further study will be necessary to fully elucidate the epidemiology
of in vitro and in vivo susceptibility to β-lactam/β-lactamase inhibitor
combinations globally and in other lineages ofM. tuberculosis. The asso-
ciation betweenMDR and XDR clinical isolates and in vitro susceptibility
to amoxicillin/clavulanate may provide effective treatment options for
patients with XDR-TB, at least in regions of high LAM4 prevalence
such as South Africa. However a recent study from Japan (Horita et al.,
2014) suggests that drug-resistant strains with other genetic back-
grounds also exhibit a similar phenotype. While the South African Na-
tional TB program includes amoxicillin/clavulanate as part of a
suggested drug regimen for XDR (Mangement of Drug-resistant
Tuberculosis Policy Guidelines, 2012), only 61% of patients in a recently
published long-term cohort of XDR in South Africa were prescribed
this drug combination for at least some part of their treatment course
(Pietersen et al., 2014). Given the poor treatment outcomes for XDR
that have been reported, the fact that β-lactam drug susceptibility test-
ing is not routinely performed, and relative safety of the drug, empiric
addition of amoxicillin/clavulanate to patientswith XDR-TB in South Af-
rica may be advisable, although the optimal dosing regimen still needs
to be established.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.05.041.
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